Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market Share

Statistics for the 2023 & 2024 Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) market share, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research APAC Sodium Glucose Cotransporter Industry Market Share

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Industry

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is highly consolidated, with major manufacturers, namely Eli Lilly, Sanofi, and Novo Nordisk, with a global and regional market presence. The joint ventures that occurred between players in the recent past helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT-2 class drug.

Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Janssen Pharmaceuticals

  4. AstraZeneca

  5. Bristol Myers Squibb

*Disclaimer: Major Players sorted in no particular order

Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market Concentration

APAC SGLT2 Inhibitors Market Report Snapshots

APAC SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)